Kereos, of St. Louis, appointed Timothy Pelura chief technology officer and Dennis Riley vice president of development.
Lifecore Biomedical Inc., of Chaska, Minn., appointed Dennis Allingham president, CEO and a member of its board.
McFarland Dewey & Co. LLC, of New York, hired Anne Devlin and Rochelle King to expand the firm's health care investment banking activities.
MDS Pharma Services, of Montreal, promoted Claire Abadie to site manager at its Geneva facility.
Merrimack Pharmaceuticals Inc., of Cambridge, Mass., appointed Vincent Simmon chief operating officer.
Metabolex Inc., of Hayward, Calif., appointed David Karpf chief medical officer.
MonoSolRx LLC, of Portage, Ind., appointed Pradeep Sanghvi vice president of pharmaceutical development.
Myogen Inc., of Denver, appointed Kirk Calhoun to its board.
Nanobac Pharmaceuticals Inc., of Tampa, Fla., named Alexander Edwards president, CEO and a board member. It also appointed Brady Millican vice president and chief operating officer, Olavi Kajander managing director and chief science and research officer, and Neva Ciftcioglu scientific adviser for the Nanobac Science and Research Institute. Jan Egberts and Stephan Rechtschaffen were appointed independent directors. New members of the advisory board were Hector Gomez, David Filer, Daniel Shoskes and Benedict Maniscalco.
Neose Technologies Inc., of Horsham, Pa., appointed Ketan Desai vice president of preclinical and clinical development.
Nobex Corp., of Research Triangle Park, N.C., appointed Russell Savre vice president of finance and administration.
NuGEN Technologies Inc., of San Carlos, Calif., appointed Elizabeth Hutt vice president of sales and service, Anne Kopf-Sill vice president of product development and John Todd vice president of marketing.
Nuvelo Inc., of Sunnyvale, Calif., appointed Barry Zubrow to its board.
Parexel International Corp., of Boston, appointed Herman Scholtz vice president and worldwide head of the clinical pharmacology business.
Peplin Biotech Ltd., of Brisbane, Australia, appointed Michael Spooner a nonexecutive member of its board.
Pharsight Corp., of Mountain View, Calif., appointed Cynthia Stephens senior vice president and chief financial officer and James Bosley senior director of product management.
ProMetic Life Sciences Inc., of Montreal, appointed Claude Lambert vice president of finance and administration. Andre Bedard now will be responsible for special projects associated with manufacturing expansion. The company also nominated Christopher Penney chief scientific officer of therapeutics and Steve Burton chief scientific officer of the enabling technology decision.
Raven Biotechnologies Inc., of South San Francisco, appointed Stephen Worsley vice president of business development.
Sonus Pharmaceuticals Inc., of Bothell, Wash., appointed Lynn Gold vice president of research and process development and Neile Grayson vice president of strategic planning and corporate development. It also promoted Dean Kessler to vice president of preclinical development.
The Immune Response Corp., of Carlsbad, Calif., appointed Kevin Reilly to its board.
The Institute for Systems Biology in Seattle appointed Mark Wingerd director of its proteomics facility.
U.S. Genomics, of Woburn, Mass., appointed J. Craig Venter to its scientific advisory board.